Ardelyx Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $450.9M+35.2% YoYTTM through 30 Jun 2026
Net Income -$55.7MTTM through 30 Jun 2026
Free Cash Flow -$17.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 90.3% |
| EBITDA Margin | -7.1% |
| Operating Margin | -10.1% |
| Net Margin | -12.4% |
Returns
-36.9%ROE
-12.3%ROA
Balance Sheet Health
Debt / Equity1.37x
Current Ratio3.34x
Net Debt-$36Mnet cash position
Cash & Equivalents$97.2M
Quality Metrics
Altman Z-Score0.10
Piotroski F-Score2 / 9
FCF Margin-4.0%
Rule of 404.6
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $407.3M
Diluted EPS-$0.23TTMFY2025: $-0.26
Dividend
No dividend
Capital Allocation
R&D Spend$87.2M
Capex Intensity0.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| IBSRELA Product Sales | $274.2M | +73.2% | View detailsExpected full-year 2026 revenue for IBSRELA to be between $410 million and $430 million, representing at least 50% growth compared to 2025. |
| XPHOZAH Product Sales | $103.6M | -35.6% | View detailsExpected full-year 2026 revenue for XPHOZAH to be between $110 million and $120 million. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.